Publication | Closed Access

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Double-blind Phase 3MedicineMetronomic TherapyClinical TrialsIcotinib Versus GefitinibBronchial NeoplasmNon-inferiority TrialCancer TreatmentOncologyRadiation OncologyLung CancerHealth Sciences